Interim Division Head, Hematology & Oncology
Interim Division Chief of Hematology/Oncology
UMH Room S9D07
Education and Training
BS 1973 Biochemistry Manhattan College, Riverdale, NY
PhD 1978 Albert Einstein College of Medicine, Bronx NY
MD 1979 Albert Einstein College of Medicine, Bronx, NY
Intern Department of Medicine, 1979 Peter Bent Brigham Hospital, HarvardMedicalSchool, Boston, MA
Resident Department of Medicine, 1980-82, Brigham & Women's Hospital, Harvard Medical School, Boston, MA
Medical Oncology Fellowship, 1982-85 Clinical Oncology Program, NCI, NIH, Bethesda, MD
I joined University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) in 2004 following a 20-year career in the U.S. Public Health Service. In that capacity, I was attending physician at NCI in the NIHClinicalCenter leading Phase I/II trials in solid tumors and lymphoma. Also at NCI, I led the Developmental Therapeutics Program, the NCI's preclinical cancer treatment drug and biological discovery and development program. In that role, I directed entry of more than 30 agents passed into clinical trials under NCI or collaborating corporate sponsorship, including Velcade ultimately approved for myeloma, Romidepsin for cutaneous lymphoma, and Halaven for breast cancer, among others. At University of Maryland, I serve as interim director of the Division of Hematology/Oncology, Department of Medicine. I am also an active Phase I investigator in the Cancer Center. I am co-editor-in-chief of Cancer Chemotherapy and Pharmacology, and serve on the Editorial Boards of The Journal of the National Cancer Institute, Cancer Research, and Molecular Cancr Therapeutics.
Phase I Cancer Drug Clinical Trials Brain tumor medical oncology
- Vaishampayan UN, Burger AM, Sausville EA, Heilbrun LK, Li J, et al. Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin. Clin Cancer Res. 2010 Jul 15;16(14):3795–804. PubMed PMID: 20525756.
- Hochhauser D, Glynne-Jones R, Potter V, Grávalos C, Sausville EA, et al. A phase II study of temozolomide in patients with advanced aerodigestive tract and colorectal cancers and methylation of the O6-methylguanine-DNA methyltransferase promoter. Mol Cancer Ther. 2013 May;12(5):809–18. PubMed PMID: 23443801.
- Lorusso PM, Edelman MJ, Bever SL, Forman KM, Sausville EA, et al. Phase I study of folate conjugate EC145 (Vintafolide) in patients with refractory solid tumors. J Clin Oncol. 2012 Nov 10;30(32):4011–6. PubMed PMID: 23032618.
- Sausville E, Lorusso P, Carducci M, Carter J, Quinn MF, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):539–49. PubMed PMID: 24448638.
I attend on the inpatient leukemia service at UMMC, and see phae I clinical trial and brain tumor patients in the outpatient setting
R44CA 195793 Sausville (co-PI) 09/21/15-08/31/17 NIH/NCI (in NCE)
Clinical Investigation of the Ceramide NanoLiposome for Advanced Solid Tumors
Role: CoPI for coordination of Phase I clinical Trial